Xu J - Search Results

1

Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer.

Chen D, Xu J, Qiao R, Zhao Y, Chu T, Han B, Zhong R. Chen D, et al. Among authors: xu j. J Oncol. 2020 Nov 19;2020:8811487. doi: 10.1155/2020/8811487. eCollection 2020. J Oncol. 2020. PMID: 33643409 Free PMC article.

2

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer.

Xu J, Chu T, Jin B, Dong X, Lou Y, Zhang X, Wang H, Zhong H, Shi C, Gu A, Xiong L, Zhao Y, Jiang L, Zhang J, Han B. Xu J, et al. Clin Lung Cancer. 2016 Jul;17(4):309-14. doi: 10.1016/j.cllc.2015.11.009. Epub 2015 Dec 1. Clin Lung Cancer. 2016. PMID: 26725853

3

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China.

Xu J, Zhang Y, Jin B, Chu T, Dong X, Yang H, Wu D, Lou Y, Zhang X, Wang H, Han B. Xu J, et al. J Cancer Res Clin Oncol. 2016 Jun;142(6):1325-30. doi: 10.1007/s00432-016-2133-4. Epub 2016 Mar 4. J Cancer Res Clin Oncol. 2016. PMID: 26942444

4

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.

Xu J, Jin B, Chu T, Dong X, Yang H, Zhang Y, Wu D, Lou Y, Zhang X, Wang H, Han B. Xu J, et al. Lung Cancer. 2016 Jun;96:87-92. doi: 10.1016/j.lungcan.2016.01.018. Epub 2016 Jan 30. Lung Cancer. 2016. PMID: 27133756

5

Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy.

Bai H, Xu J, Yang H, Jin B, Lou Y, Wu D, Han B. Bai H, et al. Among authors: xu j. Onco Targets Ther. 2016 Jul 11;9:4207-13. doi: 10.2147/OTT.S106696. eCollection 2016. Onco Targets Ther. 2016. PMID: 27471395 Free PMC article.

6

Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations.

Xu J, Zhang X, Yang H, Ding G, Jin B, Lou Y, Zhang Y, Wang H, Han B. Xu J, et al. Oncotarget. 2016 Oct 18;7(42):68442-68448. doi: 10.18632/oncotarget.12035. Oncotarget. 2016. PMID: 27637087 Free PMC article.

7

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer.

Xu J, Yang H, Fu X, Jin B, Lou Y, Zhang Y, Zhang X, Zhong H, Wang H, Wu D, Han B. Xu J, et al. J Thorac Oncol. 2017 Feb;12(2):347-353. doi: 10.1016/j.jtho.2016.09.133. Epub 2016 Oct 7. J Thorac Oncol. 2017. PMID: 27725211 Free article.

8

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China.

Xu J, Ding G, Zhang X, Jin B, Lou Y, Zhang Y, Wang H, Wu D, Han B. Xu J, et al. Onco Targets Ther. 2016 Oct 20;9:6479-6484. doi: 10.2147/OTT.S119341. eCollection 2016. Onco Targets Ther. 2016. PMID: 27799795 Free PMC article.

9

MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma.

Zhang Y, Yu K, Hu S, Lou Y, Liu C, Xu J, Li R, Zhang X, Wang H, Han B. Zhang Y, et al. Among authors: xu j. Oncotarget. 2016 Dec 13;7(50):83051-83059. doi: 10.18632/oncotarget.13031. Oncotarget. 2016. PMID: 27811371 Free PMC article.

10

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.

Xu J, Yang H, Jin B, Lou Y, Zhang Y, Zhang X, Zhong H, Wang H, Wu D, Han B. Xu J, et al. Sci Rep. 2016 Nov 4;6:36371. doi: 10.1038/srep36371. Sci Rep. 2016. PMID: 27811976 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67,574 results

Search Page

Filters